Verona Pharma price target raised to $57 from $44 at Truist

Jan 8, 2025 · Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the company’s positive Q4 revenue pre …

$57
OFF

Verona Pharma Price Target Raised To $57 From $44 At Truist

2 weeks from now

Jan 8, 2025 · Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the company’s positive Q4 revenue pre …

nasdaq.com

$74
OFF

Verona Pharma Price Target Raised To $74 From $64 At Wells Fargo

2 weeks from now

Jan 8, 2025 · Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma to $74 from $64 and keeps an Overweight rating on the shares.The firm notes preliminary Q4 …

businessinsider.com

$77
OFF

Verona Pharma Price Target Raised To $77 From $51 At BTIG

2 weeks from now

Jan 8, 2025 · BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 pre-announcement was “impressive”, …

nasdaq.com

$36
OFF

Verona Posts Sales Figures For Q4 And 2024 (VRNA:NASDAQ)

2 weeks from now

Jan 7, 2025 · Citing preliminary unaudited results on Tuesday, Verona Pharma (NASDAQ:VRNA) reported ~$36M and $42M in net product sales for Q4 and the full year 2024, respectively, …

seekingalpha.com

9%
OFF

Verona Pharma Gains As Preliminary 4Q Sales Exceed Estimates

2 weeks from now

邏 Just 1 week into 2025: These 7 AI-picked stocks are up 9%+ each Unlock Stocks Get 100% ad-free experience Verona Pharma gains as preliminary 4Q sales exceed estimates

investing.com

6%
OFF

Verona Pharma Gains As Preliminary 4Q Sales Exceed Estimates

2 weeks from now

Jan 7, 2025 · Investing.com -- Verona Pharma (NASDAQ: VRNA), the pharmaceutical company known for its pulmonary disease drug, Ohtuvayre, has reported a premarket gain of 4.6% after …

investing.com

$36
OFF

Verona Pharma Sees Q4 Net Product Sales Revenue $36M Vs. $0M A …

2 weeks from now

Jan 7, 2025 · Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 was another …

businessinsider.com

$36
OFF

Verona Pharma To Report $36 Million In Q4 Net Product Revenue

2 weeks from now

Jan 7, 2025 · Verona Pharma plc, Q3 2024 Earnings Call, Nov 04, 2024 Nov. 04: Verona Pharma's Q3 Loss Widens Nov. 04: MT Verona Pharma plc Reports Earnings Results for the …

marketscreener.com

5%
OFF

Verona Pharma (NASDAQ:VRNA) Stock Price Up 4.5% - Should …

2 weeks from now

2 days ago · Roth Capital raised Verona Pharma to a "strong-buy" rating in a research report on Friday. Finally, Truist Financial reissued a "buy" rating and issued a $57.00 price objective (up …

marketbeat.com

$36
OFF

Verona Pharma Reports Approximately $36 Million In Q4 2024 Net …

2 weeks from now

Jan 7, 2025 · Verona Pharma reports $36M in Q4 and $42M in 2024 sales for Ohtuvayre, with over 16,000 prescriptions filled. Quiver AI Summary. Verona Pharma plc has announced its …

nasdaq.com

$36
OFF

Verona Pharma Expects Preliminary Q4 Sales Of About $36 Mln …

2 weeks from now

Jan 7, 2025 · Verona Pharma plc (), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth quarter net product sales of $36 million and full …

rttnews.com

6%
OFF

Verona Pharma Soars 4.6% On Strong Q4 Sales: What

2 weeks from now

Jan 7, 2025 · Verona Pharma (NASDAQ: VRNA), a firm making waves in the pharmaceutical sector with its innovative lung disease treatment, Ohtuvayre, is basking in the glow of strong …

stockinvest.us

$36
OFF

Verona Pharma Reports Approximately $36 Million In Q4 2024 Net …

2 weeks from now

Jan 7, 2025 · In the fourth quarter of 2024, Verona Pharma announced an estimated net product sales of around $36 million, a significant increase from $0 million in Q4 2023. These sales …

wallstreetwaves.com

$36
OFF

Verona Pharma Reports Strong Ohtuvayre™ Launch And

2 weeks from now

Jan 7, 2025 · Product sales: The Company expects to report that net product sales were approximately $36 million for the fourth quarter ended December 31, 2024 (Q4 2023: $0 …

morningstar.com

65%
OFF

Wall Street Analysts See A 30.65% Upside In Verona Pharma

2 weeks from now

1 day ago · Verona Pharma PLC American Depositary Share (VRNA) closed the last trading session at $46.69, gaining 9.4% over the past four weeks, but there could be plenty of upside …

nasdaq.com

$50.57
OFF

Verona Pharma (VRNA) Stock Forecast And Price Target 2025

2 weeks from now

Learn why top analysts are making this stock forecast for Verona Pharma at MarketBeat. VRNA's current price target is $50.57. Learn why top analysts are making this stock forecast for …

marketbeat.com

45%
OFF

Verona Pharma Reports Strong Ohtuvayre™ Launch And Provides …

2 weeks from now

Jan 7, 2025 · Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre . LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) …

marketscreener.com

FAQs about Verona Pharma price target raised to $57 from $44 at Truist Coupon?

How much does Verona Pharma stock cost?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Verona Pharma is $50.57, with a high forecast of $74.00 and a low forecast of $33.00. Should I buy or sell Verona Pharma stock right now? ...

How did Verona Pharma perform in Q4?

Citing preliminary unaudited results on Tuesday, Verona Pharma (NASDAQ: VRNA) reported ~$36M and $42M in net product sales for Q4 and the full year 2024, respectively, thanks to its newly launched lung disease therapy, Ohtuvayre. ...

Should you buy Verona Pharma (vRNA)?

WA Consumer Health Privacy Policy Your privacy controls Ad Terms Feedback If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. ...

How much money did Verona (vRNA) make in 2024?

Additionally, Verona (NASDAQ: VRNA) reported roughly $400M in cash and cash equivalents as of December 31, 2024, up from $271.8M a year ago, and disclosed the sale of $100M worth of its ordinary shares in the form of ADSs as part of an “at the market” equity offering with Jefferies in Q4. Have a tip? Submit confidentially to our News team. ...

Is ohtuvayre doing well in Q4?

The firm notes preliminary Q4 sales of $36M marks the second quarter in which Ohtuvayre is tracking well above the launch comps. Wells is increasing its near-term trajectory, long-term peak sales, and efficient/M&A weight in its discounted cash flow. ...

Is vRNA a profitable bet for 'trend' investors?

Here are the key reasons why it could be a profitable bet for "trend" investors. A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. VRNA is quite a good fit in this regard, gaining 33.3% over this period. ...